The ADWP is dedicated to promoting clinical activities, teaching and translational research on autologous/allogeneic HSCT together with novel approaches of cellular therapy as specific treatment of severe Autoimmune Diseases (AD), in a specific challenge to re-induce self-tolerance by resetting the immune system.
The ADs section of the EBMT Registry is the largest database of its kind worldwide. ADs is recently facing a unique developmental phase across EBMT centres. Autologous HSCT has become an integral and standard-of-care part of treatment algorithms in multiple sclerosis (MS) and systemic sclerosis (SSc). Recently, novel cellular therapies (ie CART cells, mesenchymal cells) have been successfully adopted in ADs.
A multidisciplinary approach is key in this field, and the ADWP has the strategic task of interacting with other Autoimmune Diseases (AD) specialists and their respective scientific societies.
ADWP Team
